Maravai LifeSciences Holdings, Inc. (MRVI)

Healthcare · Pharmaceuticals · Price $7.68
Updated: Aug 31, 2026
Revenue (TTM)
$208.8M
Trailing 12 Months
Growth Rate
-25.12%
Log-Linear Regression (16Q)
Price/Sales
5.4x
Valuation Multiple
Revenue Per Share
$1.41
Sales / Shares
Gross Margin
34.89%
Pricing Power

📈 Revenue History (16 Quarters)

🧮 MRVI Revenue Breakdown

Revenue = Product Sales + Service Revenue + Other Income
Total Revenue (TTM) $208.8M
Less: Cost of Revenue $135.9M
Equals: Gross Profit $72.8M
Then: Operating Income $-117.1M
Finally: Net Income $-77.4M

Understanding Revenue

Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For MRVI, the trailing twelve month revenue is $208.8M.

Why Revenue Matters

Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.

MRVI's revenue growth rate of -25.12% (based on log-linear regression of 16 quarters) indicates significant revenue decline, which requires investigation.

Revenue vs Profitability Metrics

Free Cash Flow: $-51.9M →

The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.

Owner Earnings: $-51.9M →

Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.

Earnings Per Share: $-0.52 →

Net income per share. The bottom line result of all revenue after costs, taxes, and interest.

Net Income: $-77.4M

What remains after all expenses. Net margin shows what percentage of revenue becomes profit.

Price/Sales Ratio Analysis

MRVI's P/S ratio of 5.4x means investors pay $5.44 for every $1 of annual revenue. A P/S between 3-10 suggests investors expect continued growth and margin expansion.

Gross Margin: Revenue Quality

Gross margin of 34.89% shows how much of MRVI's revenue remains after direct costs. Gross margins between 20-40% are common in competitive industries.

Summary: MRVI Revenue Trend

Maravai LifeSciences Holdings, Inc. (MRVI) generated $208.8M in trailing twelve-month revenue, growing at -25.12% annually — a material decline Zyberno treats as a concern requiring investigation. Maravai LifeSciences Holdings, Inc.'s gross margin of 34.89% is acceptable for a Healthcare company — within the 20–40% range Zyberno considers typical for healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins. For complete financial analysis, view the full MRVI stock report on Zyberno.

Frequently Asked Questions

What is MRVI's current revenue?

Maravai LifeSciences Holdings, Inc.'s trailing twelve month (TTM) revenue is $208.8M, growing at -25.12% annually — a material decline Zyberno treats as a concern requiring investigation.

Is MRVI's revenue growing?

Maravai LifeSciences Holdings, Inc. (MRVI) generated $208.8M in trailing twelve-month revenue, growing at -25.12% annually — a material decline Zyberno treats as a concern requiring investigation. Maravai LifeSciences Holdings, Inc.'s gross margin of 34.89% is acceptable for a Healthcare company — within the 20–40% range Zyberno considers typical for healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins.

What is MRVI's gross margin?

Maravai LifeSciences Holdings, Inc.'s gross margin of 34.89% is acceptable for a Healthcare company — within the 20–40% range Zyberno considers typical for healthcare businesses where IP protection, regulatory moats, and service complexity shape gross margins.

What is MRVI's Price/Sales ratio?

MRVI's P/S ratio is 5.4x, meaning the market values the company at 5.4 times its annual revenue.

How does revenue differ from profit?

Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. MRVI's revenue is $208.8M with a net income of $-77.4M, showing a net profit margin of -37.1%.

📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
🛡️
Margin of Safety
Valuation Gap
🎯
Expected Return
Projected Annual
Click any metric for full methodology and detailed analysis

📊 Full MRVI Stock Report

See MRVI's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

💵 MRVI Free Cash Flow

Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.

💰 MRVI Owner Earnings

Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.

📈 MRVI Earnings Per Share

Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.

🎯 MRVI Earnings Surprise (SUE)

See whether MRVI is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

📊 MRVI Revenue

Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.

💰 MRVI Net Income

Analyze the bottom-line profit, P/E ratio, and net profit margin trends.

🔶 MRVI Operating Income

Analyze EBIT, operating margin, and core business profitability before interest and taxes.

💜 MRVI Gross Profit

Analyze gross margin, pricing power, and profitability before operating expenses.

View Full MRVI Report Find More Quality Stocks
Scroll to Top